140 related articles for article (PubMed ID: 36497326)
21. The association between clinical parameters and resectability in stage III non-small cell lung cancer, and a combination of N2 lymph node burden and lung immune prognostic index score as a potential biomarker.
Kim S; Lim JU; Kang HS; Shin AY; Yeo CD; Kim SK; Park CK; Kim SJ; Lee SH; Kim JW
Transl Lung Cancer Res; 2023 Jan; 12(1):79-95. PubMed ID: 36762065
[TBL] [Abstract][Full Text] [Related]
22. [Effect of dNLR and LIPI scores on the prognosis of elderly patients with non-surgical treatment of non-small cell lung cancer].
Xie JH; Liu MM; Sun NN; Zhang L; Zhang HZ
Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):975-980. PubMed ID: 36164700
[No Abstract] [Full Text] [Related]
23. Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer.
Zhao Q; Li B; Xu Y; Wang S; Zou B; Yu J; Wang L
Cancer Med; 2021 Sep; 10(18):6291-6303. PubMed ID: 34390218
[TBL] [Abstract][Full Text] [Related]
24. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of the lung immune prognostic index in advanced non-small cell lung cancer patients under nivolumab monotherapy.
Ruiz-Bañobre J; Areses-Manrique MC; Mosquera-Martínez J; Cortegoso A; Afonso-Afonso FJ; de Dios-Álvarez N; Fernández-Núñez N; Azpitarte-Raposeiras C; Amenedo M; Santomé L; Fírvida-Pérez JL; García-Campelo R; García-González J; Casal-Rubio J; Vázquez S
Transl Lung Cancer Res; 2019 Dec; 8(6):1078-1085. PubMed ID: 32010585
[TBL] [Abstract][Full Text] [Related]
26. Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer.
Mountzios G; Samantas E; Senghas K; Zervas E; Krisam J; Samitas K; Bozorgmehr F; Kuon J; Agelaki S; Baka S; Athanasiadis I; Gaissmaier L; Elshiaty M; Daniello L; Christopoulou A; Pentheroudakis G; Lianos E; Linardou H; Kriegsmann K; Kosmidis P; El Shafie R; Kriegsmann M; Psyrri A; Andreadis C; Fountzilas E; Heussel CP; Herth FJ; Winter H; Emmanouilides C; Oikonomopoulos G; Meister M; Muley T; Bischoff H; Saridaki Z; Razis E; Perdikouri EI; Stenzinger A; Boukovinas I; Reck M; Syrigos K; Thomas M; Christopoulos P
ESMO Open; 2021 Oct; 6(5):100254. PubMed ID: 34481329
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of the Lung Immune Prognostic Index in Non-Small Cell Lung Cancer Patients Treated With Systemic Therapy: A Retrospective Study and Meta-Analysis.
Huang L; Han H; Zhou L; Chen X; Xu Q; Xie J; Zhan P; Chen S; Lv T; Song Y
Front Oncol; 2021; 11():670230. PubMed ID: 34249708
[TBL] [Abstract][Full Text] [Related]
28. A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study.
Deng K; Wang L; Liu Y; Li X; Hou Q; Cao M; Ng NN; Wang H; Chen H; Yeom KW; Zhao M; Wu N; Gao P; Shi J; Liu Z; Li W; Tian J; Song J
EClinicalMedicine; 2022 Sep; 51():101541. PubMed ID: 35813093
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.
Galland L; Le Page AL; Lecuelle J; Bibeau F; Oulkhouir Y; Derangère V; Truntzer C; Ghiringhelli F
Oncoimmunology; 2021; 10(1):1957603. PubMed ID: 34377595
[TBL] [Abstract][Full Text] [Related]
30. The Prediction Potential of the Pretreatment Lung Immune Prognostic Index for the Therapeutic Outcomes of Immune Checkpoint Inhibitors in Patients With Solid Cancer: A Systematic Review and Meta-Analysis.
Liu H; Yang XL; Yang XY; Dong ZR; Chen ZQ; Hong JG; Li T
Front Oncol; 2021; 11():691002. PubMed ID: 34631525
[TBL] [Abstract][Full Text] [Related]
31. Predictive Factors Correlated with the Development of Immune-Related Adverse Events in Patients with Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors.
Sonehara K; Tateishi K; Araki T; Komatsu M; Akahane J; Yamamoto H; Hanaoka M
Cancer Manag Res; 2022; 14():427-435. PubMed ID: 35140520
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibitors alone or in combination with chemotherapy for treatment of advanced non-small cell lung cancer after first-line platinum-based chemotherapy: A propensity score matching analysis.
Qiu L; Gao S; Du S; Sun S; Liang Y; Sun Z; Li T; Jia G; Li K; Sun X; Jiao S; Zhao X
Front Oncol; 2022; 12():974227. PubMed ID: 36523994
[TBL] [Abstract][Full Text] [Related]
33. The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index.
Zhang T; Yang X; Zhao J; Xia L; Wang Q; Jin R; Zhou L; Zhang B; Zhao J; Li H; Li W; Xia Y
Front Oncol; 2021; 11():690093. PubMed ID: 34150659
[TBL] [Abstract][Full Text] [Related]
34. Patient-reported outcomes as a prognostic marker of survival in patients with advanced nonsmall cell lung cancer treated with immunotherapy.
Hopkins AM; Wagner J; Kichenadasse G; Modi N; Rowland A; Sorich MJ
Int J Cancer; 2020 Dec; 147(11):3085-3089. PubMed ID: 32492185
[TBL] [Abstract][Full Text] [Related]
35. Prognostic role of pretreatment lung immune prognostic index in extensive-stage small-cell lung cancer treated with platinum plus etoposide chemotherapy.
Qi W; Zhao S; Chen J
Cancer Biomark; 2021; 31(2):177-185. PubMed ID: 33896825
[TBL] [Abstract][Full Text] [Related]
36. Prognostic Value of the Pretreatment Lung Immune Prognostic Index in Advanced Small Cell Lung Cancer Patients Treated With First-Line PD-1/PD-L1 Inhibitors Plus Chemotherapy.
Li L; Pi C; Yan X; Lu J; Yang X; Wang C; Li X; Zhang S; Zhang Z; Sun Y; Hu Y
Front Oncol; 2021; 11():697865. PubMed ID: 34692478
[TBL] [Abstract][Full Text] [Related]
37. Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
Petrillo LA; El-Jawahri A; Nipp RD; Lichtenstein MRL; Durbin SM; Reynolds KL; Greer JA; Temel JS; Gainor JF
Cancer; 2020 May; 126(10):2288-2295. PubMed ID: 32142165
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
39. Prognostic Nutritional Index and Lung Immune Prognostic Index as Prognostic Predictors for Combination Therapies of Immune Checkpoint Inhibitors and Cytotoxic Anticancer Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer.
Tanaka S; Uchino J; Yokoi T; Kijima T; Goto Y; Suga Y; Katayama Y; Nakamura R; Morimoto K; Nakao A; Hibino M; Tani N; Takeda T; Yamaguchi H; Tachibana Y; Takumi C; Hiraoka N; Takeshita M; Onoi K; Chihara Y; Taniguchi R; Yamada T; Matsui Y; Hiranuma O; Morimoto Y; Iwasaku M; Tokuda S; Kaneko Y; Yamada T; Takayama K
Diagnostics (Basel); 2022 Feb; 12(2):. PubMed ID: 35204513
[TBL] [Abstract][Full Text] [Related]
40. Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score.
Pierro M; Baldini C; Auclin E; Vincent H; Varga A; Martin Romano P; Vuagnat P; Besse B; Planchard D; Hollebecque A; Champiat S; Marabelle A; Michot JM; Massard C; Mezquita L
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
